Luan Nan-Nan, Wu Lang, Gong Ting-Ting, Wang Yong-Lai, Lin Bei, Wu Qi-Jun
Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang, People's Republic of China.
Cancer Causes Control. 2015 Jan;26(1):65-78. doi: 10.1007/s10552-014-0483-2. Epub 2014 Oct 31.
Although the relationship between oral contraceptive (OC) use and colorectal cancer (CRC) risk has been studied extensively, the results of epidemiological studies are controversial. Therefore, we carried out a meta-analysis of epidemiological studies to summarize the available evidence and to quantify the potential dose-response relation.
We searched PubMed database for studies of OC use and CRC risk that were published until the end of March 2014. Random- and fixed-effects models were applied to estimate summary relative risks (RRs) and 95 % confidence intervals (CIs).
Twelve cohorts and seventeen case-control studies with a total of 15,790 CRC cases were included in the final analysis. The summary RR for the ever versus never category of OC use was 0.82 (95 % CI 0.76-0.88). Similar result was observed when we compared the longest duration of OC use with the shortest duration (RR = 0.86, 95 % CI 0.76-0.96). Furthermore, the results of stratified analysis were comparable to those of overall meta-analysis. In dose-response analysis, significant inverse associations emerged in nonlinear models for the duration of OC use and CRC (P nonlinearity = 0.001). The greatest risk reduction was observed when the duration of OC use was approximately 42 months. There was moderate heterogeneity in the analysis, and no evidence of small-study bias was observed.
Based on the findings of this meta-analysis, ever use of OC is associated with lower risk of CRC. Additionally, there is a statistically significant nonlinear inverse association between the duration of OC use and CRC risk.
尽管口服避孕药(OC)的使用与结直肠癌(CRC)风险之间的关系已得到广泛研究,但流行病学研究结果仍存在争议。因此,我们开展了一项流行病学研究的荟萃分析,以总结现有证据并量化潜在的剂量反应关系。
我们在PubMed数据库中检索了截至2014年3月底发表的关于OC使用与CRC风险的研究。应用随机效应模型和固定效应模型来估计汇总相对风险(RR)和95%置信区间(CI)。
最终分析纳入了12项队列研究和17项病例对照研究,共15790例CRC病例。曾经使用OC与从未使用OC相比的汇总RR为0.82(95%CI 0.76 - 0.88)。当我们比较OC使用最长持续时间与最短持续时间时,观察到了类似结果(RR = 0.86,95%CI 0.76 - 0.96)。此外,分层分析结果与总体荟萃分析结果相当。在剂量反应分析中,OC使用持续时间与CRC的非线性模型中出现了显著的负相关(P非线性 = 0.001)。当OC使用持续时间约为42个月时,观察到最大的风险降低。分析中存在中度异质性,未观察到小研究偏倚的证据。
基于这项荟萃分析的结果,曾经使用OC与较低的CRC风险相关。此外,OC使用持续时间与CRC风险之间存在统计学上显著的非线性负相关。